A Phase I, Open-Label, Multicentre, Dose-Escalation Study to Investigate the Safety and Pharmacokinetics of AZD8835 in Patients With Advanced Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2016
Price : $35 *
At a glance
- Drugs AZD 8835 (Primary) ; Fulvestrant (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 07 Oct 2016 Status changed from active, no longer recruiting to completed.
- 28 Jun 2016 Status changed from recruiting to active, no longer recruiting.